D&D Pharmatech (XKRX:347850) Change In Receivables : ₩584 Mil (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech Change In Receivables?

D&D Pharmatech's change in receivables for the quarter that ended in Mar. 2025 was ₩2,509 Mil. It means D&D Pharmatech's Accounts Receivable declined by ₩2,509 Mil from Dec. 2024 to Mar. 2025 .

D&D Pharmatech's change in receivables for the fiscal year that ended in Dec. 2024 was ₩-3,921 Mil. It means D&D Pharmatech's Accounts Receivable increased by ₩3,921 Mil from Dec. 2023 to Dec. 2024 .

D&D Pharmatech's Accounts Receivable for the quarter that ended in Mar. 2025 was ₩0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. D&D Pharmatech's Days Sales Outstanding for the three months ended in Mar. 2025 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. D&D Pharmatech's liquidation value for the three months ended in Mar. 2025 was ₩797 Mil.

D&D Pharmatech Change In Receivables Historical Data

The historical data trend for D&D Pharmatech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D&D Pharmatech Change In Receivables Chart

D&D Pharmatech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

195.91

897.49

-231.50

-3,617.52

-3,921.11

D&D Pharmatech Quarterly Data
	Dec18	Dec19	Dec20	Dec21	Dec22	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial								-1,996.26	2,243.25	209.27	-4,377.37	2,509.07

D&D Pharmatech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩584 Mil.

D&D Pharmatech (XKRX:347850) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

D&D Pharmatech's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	1413.462	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, D&D Pharmatech's accounts receivable are only considered to be worth 75% of book value:

D&D Pharmatech's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	26146.873	-	25350.302	+	0.75 * 0	+	0.5 * 0
=	797

D&D Pharmatech Change In Receivables Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

D&D Pharmatech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR

Website

http://www.ddpharmatech.com

D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech Headlines

No Headlines